Zeldox

Quick links to important sections

Zeldox

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zeldox

Quick Facts

Property Description
Active ingredient Ziprasidone (as Hydrochloride or Mesylate salt)
Form Oral Capsule and Powder for Intramuscular Injection
Pharmacological class Atypical Antipsychotic (Second-Generation Antipsychotic)
General purpose Agent for managing severe disruptions in thought and mood
Origin Synthetic compound

What Type of Medicine is Ziprasidone?

Ziprasidone is the active ingredient in this prescription-only medication, which is classified as an Atypical Antipsychotic, also known as a Second-Generation Antipsychotic (SGA). This compound is a psychotropic agent designed for stabilizing the severe disruptions in thought and emotional patterns that characterize certain disorders. It is classified as a Serotonin-Dopamine Antagonist (SDA), which indicates the medicine's general therapeutic purpose is to modulate key signaling pathways in the central nervous system, helping to restore psychological stability.

Composition and Forms of Ziprasidone

The Ziprasidone compound is a synthetic compound, specifically a Benzisothiazolylpiperazine derivative, manufactured as a single product (monotherapy). The medication is supplied in two distinct drug forms to accommodate various patient needs. The primary forms are the Oral Capsule, intended for sustained treatment, and the Powder for solution for injection (Intramuscular Injection), utilized for rapid intervention. This flexibility in delivery ensures the compound can be administered for both acute stabilization and chronic maintenance, a feature that allows for its versatility.

How Does Ziprasidone Generally Help?

Ziprasidone generally helps by performing a targeted balancing of brain messengers, which promotes a more stable mental state. This SDA compound works by modulating the activity of the brain’s key chemical messengers, including dopamine and serotonin. By fine-tuning these systems, the medicine helps to control excessive or imbalanced signaling, which contributes to the management of disorganized mental states and supports the maintenance of a calmer, more stable psychological function.

What side effects are possible with Zeldox?

Possible side effects and safety information

The safety profile of Zeldox (ziprasidone) is formally defined by regulatory agencies, classifying potential adverse reactions by frequency and physiological system. As an Atypical Antipsychotic, its officially documented side effects commonly involve the Nervous System and Gastrointestinal System.

Frequency-Classified Adverse Reactions

Adverse reactions classified as Common (based on clinical trial data) often include somnolence (sleepiness), dizziness, Extrapyramidal Symptoms (EPS) such as akathisia (restlessness), and nausea or vomiting.


Serious Adverse Reactions and Constraints

The regulatory safety profile highlights several serious risks that warrant careful consideration. A primary constraint is the potential for QT interval prolongation, which can lead to life-threatening heart arrhythmias. For this reason, the medicine is contraindicated in patients with a known history of QT prolongation, recent heart attack, or uncompensated heart failure.

Other serious adverse events documented in official labeling include Neuroleptic Malignant Syndrome (NMS), Tardive Dyskinesia (TD) associated with long-term use, and rare but severe skin reactions like DRESS syndrome.


Population-Specific Safety Notes

Official documents include specific warnings for certain populations. The drug is not approved for the treatment of psychosis in older adults with dementia, due to an increased risk of death and cerebrovascular adverse reactions (stroke/TIA) observed with this class of medication. Furthermore, exposure during the third trimester of pregnancy may result in extrapyramidal and/or withdrawal symptoms in the newborn (neonate).

Overdose and Emergency Response

Overdose and when to seek help

This information describes the documented manifestations and mandatory emergency actions for Ziprasidone overdose, strictly as stated in government regulatory documents.


Overdose Scope

Feature Official Regulatory Statement
Documented overdose presentations Clinical manifestations include drowsiness (somnolence), slurred speech, anxiety, uncontrollable shaking, and sudden movements. Severe presentations include seizure and coma.
Physiological systems affected Primary concern is the Cardiovascular System due to QTc interval prolongation risk, and the Central Nervous System due to profound CNS depression.
Dose-related or exposure-related factors Overdose risk is associated with the ingestion of amounts above the prescribed therapeutic dose.
Population-specific overdose notes Caution is advised for intramuscular administration in patients with impaired renal function due to excipient clearance.
Emergency-response statements Seek immediate medical attention for any suspected overdose.
When immediate medical help is required Call emergency services immediately if the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened. Contact the poison control helpline is also required.

Overdose Classifications (High-Level)

Classification/Basis Official Regulatory Statement
Severity classification Overdose may be associated with life-threatening outcomes, particularly due to the risk of Torsades de Pointes (TdP), seizure, and coma.
Overdose-context constraints Management is limited to symptomatic and supportive treatment, as no specific antidote is known.

Official Overdose Statements

  • Overdose presents with signs of severe CNS depression and potential uncontrollable movements.
  • The most critical risk is QTc interval prolongation, which necessitates specialized continuous cardiac monitoring.
  • Treatment procedures include gastrointestinal decontamination (e.g., activated charcoal) and managing hypotension as part of supportive care.

Regulatory documents define the overdose profile primarily by severe CNS manifestations and the risk of life-threatening cardiac arrhythmias. This dictates that immediate medical help must be sought for any severe clinical signs, particularly since no specific antidote is available, confining the management strategy to thorough supportive care and essential monitoring.

Therapeutic Uses of Zeldox

What Zeldox Treats: Main Uses and Benefits

Zeldox (ziprasidone) is a prescription medication utilized to support the management of symptoms associated with specific serious mental health conditions. It is indicated for the treatment of schizophrenia in adults, and for the acute treatment and long-term maintenance of manic or mixed episodes related to Bipolar I Disorder. The medication is also utilized for the prompt management of acute agitation in patients with schizophrenia.

Treatment with Zeldox is intended to support control over challenging symptoms such as hallucinations, delusions, and disorganized thought processes in schizophrenia. In bipolar disorder, the medication is used to assist in stabilizing mood and managing the high energy, decreased need for sleep, and irritability characteristic of manic episodes.

Quick Fact: Relief for Agitation Zeldox, in its injectable form, is administered to assist in the rapid control of severe agitation associated with schizophrenia in a clinical setting.

Eligibility and Restrictions for Use

Who can and cannot use Zeldox?

The official regulatory profile for Zeldox (ziprasidone) strictly defines the patient populations eligible for its use, based primarily on pre-existing cardiac conditions and age.

Population Eligibility Status Patient Group
Allowed Use Adults (18 years and older) for approved indications; Adolescents (age 10–17) for acute manic or mixed episodes of Bipolar I disorder.
Contraindicated Patients with a known history of QT prolongation, recent acute myocardial infarction, or uncompensated heart failure.
Contraindicated Patients taking, or within 14 days of stopping, Monoamine Oxidase Inhibitors (MAOIs), or concurrent use with other QT-prolonging medicines.
Not Approved Older adults with dementia-related psychosis (due to increased mortality risk).

Conditional and Restricted Use

Use requires caution and specific regulatory consideration in several populations. The safety and efficacy of Zeldox have not been established for children and adolescents with schizophrenia. The injectable form has limited experience in the elderly. Patients with hepatic impairment should be managed with caution, and lower doses may be considered. Use should be avoided in patients with uncorrected electrolyte imbalances, such as hypokalemia or hypomagnesemia, and in those with pre-existing low white blood cell counts, which require monitoring. Zeldox is not recommended during breastfeeding and is used in pregnancy only if the potential benefit justifies the potential risk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Contraindicated Combinations and Associated Risks

Co-administration of Zeldox with any medicinal product that has demonstrated QT interval prolongation is strictly prohibited. This includes Class IA and Class III antiarrhythmic medicines, as concurrent use may result in additive QT prolongation, increasing the risk of potentially fatal ventricular arrhythmias such as Torsade de Pointes. Use with Monoamine Oxidase Inhibitors (MAOIs) is also contraindicated due to an increased risk of Serotonin Syndrome.

Pharmacokinetic Interactions

Zeldox is metabolized in part by the enzyme CYP3A4. Co-administration with the strong CYP3A4 inhibitor ketoconazole officially results in an increase in Zeldox systemic exposure (AUC) by approximately 35–40%. Conversely, co-administration with the strong CYP3A4 inducer carbamazepine causes a decrease in Zeldox systemic exposure by approximately 35%.

Other Pharmacodynamic Interactions

Caution is advised when Zeldox is taken with other Centrally Acting Drugs, including alcohol, due to the potential for additive effects such as increased sedation or CNS depression. Additionally, Zeldox may antagonize the therapeutic effects of dopamine agonists used for conditions such as Parkinson’s disease.

Mechanism of Action

How Zeldox Works

Zeldox (ziprasidone) is characterized by simultaneous, high-affinity modulation of multiple key neurochemical systems, defined by a pattern of multi-target interaction through both blockade and augmentation.

Dual Antagonism and Central Signaling Balance

The primary action involves high-affinity antagonism at the Dopamine D2 and Serotonin 5-HT2 A receptors. This dual blockade modifies the transduction of excessive central signaling within pathways associated with signal transmission and influences central signaling pathways.

Serotonergic and Noradrenergic Augmentation

Unique to its profile is agonism at the 5-HT1 A receptor combined with inhibition of the Serotonin and Norepinephrine Transporters (SERT/NET). This simultaneous action increases the functional availability and signaling strength of these monoamines in specific limbic and cortical pathways, altering signaling dynamics.

Peripheral and Autonomic Modulation

Beyond the brain, the mechanism includes antagonism of the alpha1 adrenergic and Histamine H1 receptors. Crucially, the molecule also acts as a blocker of the hERG potassium ion channel in the heart. These interactions result in measurable physiological changes, including an influence on peripheral vascular tone and the prolongation of cardiac electrical repolarization.

Dosage and Administration Information

How to Use Zeldox: General Administration Guidelines

Ziprasidone (Zeldox) is administered using two distinct routes and forms, each designed for a specific phase of treatment. The primary forms are the Oral Capsule and the Powder for Injection for intramuscular (IM) use, which dictates the overall usage protocol.

Standard Dosing and Frequency

Indication and Form Standard Adult Dosing Regimen Frequency and Constraint
Schizophrenia (Oral) Initial: 20 mg twice daily. Maintenance Range: 20 mg to 80 mg twice daily. Maximum recommended: 80 mg twice daily (160 mg/day total). Twice daily (b.i.d.). Adjustments require not less than 2 days between changes.
Acute Agitation (IM) 10 mg or 20 mg per injection. Maximum daily dose: 40 mg. 10 mg may be repeated every 2 hours; 20 mg may be repeated every 4 hours. Use is limited to a maximum of 3 consecutive days.

Administration Requirements and Duration

Oral Administration Context: The oral capsule must be taken with food to ensure the appropriate amount of the medicine is absorbed by the body. The capsules must be swallowed whole and should not be opened, crushed, or chewed. The oral form is intended for long-term maintenance treatment of schizophrenia and bipolar disorder.

Intramuscular Administration Context: The IM injection is strictly for short-term, acute use for rapid stabilization. The powder must be reconstituted with sterile water for injection prior to administration. Co-administration of the IM injection while a patient is receiving the oral form is not recommended.

Population Considerations: The oral formulation requires no dose adjustment for renal impairment. However, use of the IM form requires caution due to the formulation's excipient. A lower oral starting dose may be considered for older adults.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Zeldox (Ziprasidone)

This overview summarizes the official clinical research and regulatory evidence regarding Zeldox (ziprasidone) according to the types of studies conducted, the outcomes they measured, and what remains unclear in the research landscape. This information is intended to provide context about the medicine’s clinical evaluation and is not a substitute for professional medical advice.


Evidence for Use in Schizophrenia Treatment

The clinical evaluation of oral ziprasidone in the context of schizophrenia utilized short-term (4- to 6-week) Randomized Controlled Trials (RCTs). These studies compared observed measurements from groups assigned to ziprasidone against groups assigned to an inactive substance (placebo). Researchers focused on outcomes related to episodic or acute changes in core psychotic symptoms, which were measured using standardized rating scales. For long-term use, the research also included maintenance trials designed to observe patients over a period of up to one year after their symptoms had stabilized.

The long-term studies examined the time interval to a recurrence of symptoms. Those studies reported that the measured time to recurrence was distinct in the group assigned to continue ziprasidone compared to the group assigned to placebo over the one-year follow-up period. Despite this, comparative evidence is lacking for direct, large-scale comparisons of long-term continuation rates against many other medications in the same class.


Evidence for Bipolar I Disorder (Manic/Mixed Episodes)

Research for the use of oral ziprasidone in conditions characterized by fluctuating or episodic manifestations, specifically Bipolar I Disorder, involved short-term placebo-controlled RCTs. The studies observed responses over defined time intervals, typically 3 to 4 weeks, to measure changes in manic symptom intensity. Research also explored the use of ziprasidone as an adjunct (add-on) to other medications used to manage mood. In this context, studies monitored the time to a new mood episode over a period of about 6 months.

Acute Agitation Research (Intramuscular Formulation)

Specialized, very short-term, double-blind, controlled trials were conducted for the intramuscular (IM) injection. Research was focused on outcomes describing episodic or acute changes in agitation levels, measured at rapid time intervals. Studies reported that changes in measured agitation scores were observed in the short-term, with the data showing distinct patterns compared to placebo measurements at the 2-hour assessment point. This IM formulation is intended only for rapid, acute stabilization.


The Study Landscape: Key Limitations and Areas for Future Research

The research base for ziprasidone was developed through studies that contribute to understanding symptom patterns in the specific conditions examined. However, the evidence highlights what is known—and what is still uncertain.

Key research limitation frames include:

  • Limited information for long-term outcomes: Data are still emerging regarding the sustained impact on outcomes reflecting daily functioning or activity level.
  • Subgroup findings are uncertain: The evidence quality varies across studies when analyzing outcomes in small, specialized patient groups.

Frequently Asked Questions (FAQ)

Common questions about Zeldox (FAQ)


Q: Is Zeldox considered a new or old type of medicine for its uses?

A: Zeldox (ziprasidone) is officially classified as an Atypical Antipsychotic, also known as a Second-Generation Antipsychotic (SGA). This classification places it among the more modern types of medication used to help manage severe disruptions in thought and mood.


Q: What happens if I miss a dose of Zeldox?

A: Official prescribing information advises consulting a healthcare provider for specific instructions regarding a missed dose. Exceeding the prescribed amount is generally not recommended, as missing doses may increase the risk of symptoms worsening (relapse).


Q: Can Zeldox cause changes in weight?

A: Official product information states that weight gain is a reported adverse reaction associated with Zeldox. Because of the risk of metabolic changes with this class of medication, patients are typically monitored for changes in their weight during treatment.


Q: Is there a generic version of Zeldox available?

A: Yes, the active ingredient, ziprasidone hydrochloride, is available in a generic capsule form. Regulatory documents list the generic formulation alongside the brand name product.


Q: What are the typical warnings about stopping Zeldox suddenly?

A: Official warnings advise against suddenly stopping this medication or changing the dose without first consulting a healthcare provider. Discontinuation can increase the risk of symptoms worsening or may lead to certain withdrawal-like symptoms.


Q: Can Zeldox cause vision problems?

A: Adverse event reporting indicates that abnormal vision and certain uncontrolled eye movements, such as oculogyric crisis, have been reported in rare cases. These events are part of the detailed safety profile for Zeldox.


Q: What is the half-life of Zeldox?

A: Pharmacokinetic data from regulatory sources confirm that the mean terminal half-life of the oral capsule is approximately 7 hours. The half-life is the amount of time it takes for the concentration of the drug in the body to be reduced by half.


Q: Can Zeldox cause confusion or memory issues?

A: Regulatory information includes a warning about the potential for cognitive and motor impairment. Because the medication may cause drowsiness, it can impair judgment and thinking. Regulatory information advises caution when operating machinery or driving, especially when beginning treatment.


Q: Does Zeldox have a risk of dependence or addiction?

A: Formal regulatory evaluation indicates that Zeldox is not a controlled substance and does not have a known risk for causing physical or mental dependence. However, abrupt discontinuation is generally advised against due to the risk of relapse or withdrawal symptoms.


Q: What is the connection between Zeldox and diabetes or blood sugar?

A: Official labeling notes that atypical antipsychotics, including Zeldox, have been associated with metabolic changes like high blood sugar (hyperglycemia) and diabetes mellitus. Monitoring for blood glucose levels is a standard practice for individuals with risk factors, both before and during treatment.


Q: What are the official uses of Zeldox as described by the FDA or other agencies?

A: According to official regulatory indications, Zeldox is used for the treatment of schizophrenia and the acute treatment of bipolar manic or mixed episodes. The oral form is also indicated as an adjunct for bipolar maintenance treatment, while the intramuscular form is used for acute agitation in schizophrenia.


Q: Does Zeldox affect sex drive or sexual function?

A: Adverse event reporting indicates that abnormalities in sexual function have been reported. This includes conditions such as hyperprolactinemia (elevated hormone levels) and a serious but rare event called priapism (a prolonged, painful erection).


Q: How quickly does Zeldox typically start working after you begin taking it?

A: Official patient information states that improvements in certain severe symptoms, like hallucinations and disorganized thinking, may begin within the first 1 to 2 weeks. However, it can take anywhere from 2 to 3 months for a person to experience the full benefits of the medication.


Q: Can you drive while taking Zeldox?

A: The regulatory label advises caution regarding driving or operating machinery until the individual knows how the medication affects them. This is because Zeldox commonly causes drowsiness and can impair thinking and motor skills.


Q: What should I know about taking Zeldox long-term?

A: Treatment for conditions like schizophrenia is often intended for long-term maintenance. Official safety information indicates that a serious condition called Tardive Dyskinesia (TD), which causes involuntary movements, is associated with the long-term use of this class of medication, requiring ongoing monitoring.


Q: Are there any specific foods or drinks to avoid while taking Zeldox?

A: The official product label specifically advises caution with the use of alcohol. This is due to the potential for alcohol to increase the central nervous system effects of the medication, potentially leading to greater sedation or impairment.


Q: What are the signs of a serious allergic reaction to Zeldox?

A: Regulatory warnings cite severe skin reactions, including DRESS syndrome, which require prompt attention. Signs can include fever, chills, rash, blisters, peeling skin, or sores. The occurrence of these symptoms is a signal to seek prompt evaluation from a healthcare professional.


Q: How long do most people stay on Zeldox?

A: For the treatment of schizophrenia, the medication is generally intended for lifelong maintenance therapy. For acute manic episodes, however, official research does not support treatment lasting longer than about three weeks once symptoms have subsided.


Q: What is the purpose of the black box warning on Zeldox?

A: The medication carries a Boxed Warning required by regulatory agencies. This warning is about the increased risk of death when this class of medication is used to treat psychosis in elderly patients with dementia. Zeldox is not approved for that condition.


Q: Does Zeldox affect blood pressure?

A: Official safety information notes the risk of orthostatic hypotension. This is a drop in blood pressure that can occur when standing up too quickly, potentially leading to dizziness or fainting. This effect is related to how the drug works on certain receptors in the body.


Q: Does Zeldox interact with herbal supplements like St. John's Wort?

A: Herbal products that act as strong CYP3A4 inducers or have properties similar to Monoamine Oxidase Inhibitors (MAOIs) should be used with caution or avoided. It is important to discuss all supplements, including herbal products, with a healthcare professional, as they can alter how the body processes Zeldox.


Q: What kind of monitoring is typically required while taking Zeldox?

A: Due to the potential for cardiac and metabolic changes, required monitoring typically includes an EKG (electrocardiogram) before and during treatment. Additionally, patients are monitored for metabolic changes such as blood glucose, lipids, and weight.


Q: Is Zeldox a mood stabilizer?

A: Zeldox is officially classified as an Atypical Antipsychotic. However, it is also indicated for use in bipolar I disorder, specifically for acute manic or mixed episodes and as an adjunct to other agents for maintenance treatment.

How should Zeldox be stored and disposed of?

How to Store and Dispose of Zeldox (Ziprasidone)

Official regulatory documentation provides specific requirements for storing and disposing of Zeldox (ziprasidone) capsules and the powder for injection.

Storage Requirements

Product Form Temperature and Protection Stability Constraint
Oral Capsules Store at controlled room temperature: 20^circ to 25 C (68^circ to 77 F), protected from moisture. Keep in the original container. Must not be frozen.
Injection Powder Store intact vial below 30 C and protect from light. Reconstituted solution is stable for 24 hours at room temperature or 7 days if refrigerated (2^circ to 8 C).

All forms must be kept out of the sight and reach of children to prevent accidental access.

Disposal Instructions

Unused or expired Zeldox product must be disposed of in accordance with local regulations for pharmaceutical waste. The medication should not be discarded in household trash or poured down a drain unless explicitly instructed by a health authority.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zeldox found in:

A-Z Index: